stars 1 stars 2 stars 3

Evercyte - the pharmacocellomicsTM company. Vision Acceleration of drug finding and development by reduction of development time and cost by introducing panels of immortalized human cell strains for drug screening strategies. Evercyte will establish the new concept of “pharmacocellomicsTM” in the field of pre-clinical developments. Therefore, we will provide primary cells from different patients and tissues that are immortalized by telomerase or other strategies (SV40; SNEV) that we have established. Thus we guarantee cell strains with the most similar phenotype to the primary cells in sufficient amounts to perform reproducible preclinical drug testing. We will deliver (i) single immortalized cell strains including mesenchymal stem cells that can be differentiated to the cell type of interest; (ii) cell panels including sufficient cell strains of different tissues and/or donors of different status (healthy, diseased, young, old, etc) in order to generate statistically meaningful data that allow to estimate drug efficiencies and toxicity with high predictive power. Finally, (iii) we will establish customer-tailored immortalized cell strains according to the needs of specific customers.

Evercyte GmbH Questions

The Evercyte GmbH annual revenue was $396000 in 2026.

Regina Grillari is the Betriebsdirektorin (COO) of Evercyte GmbH.

2 people are employed at Evercyte GmbH.

The NAICS codes for Evercyte GmbH are [541, 54171, 541714, 54, 5417].

The SIC codes for Evercyte GmbH are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users